Literature DB >> 27787742

[18F]Fluorocholine PET/CT Imaging of Liver Cancer: Radiopathologic Correlation with Tissue Phospholipid Profiling.

Sandi A Kwee1,2, Miles M Sato3, Yu Kuang4, Adrian Franke5, Laurie Custer5, Kyle Miyazaki6, Linda L Wong5.   

Abstract

PURPOSE: [18F]fluorocholine PET/CT can detect hepatocellular carcinoma (HCC) based on imaging the initial steps of phosphatidylcholine synthesis. To relate the diagnostic performance of [18F]fluorocholine positron emission tomography (PET)/x-ray computed tomography (CT) to the phospholipid composition of liver tumors, radiopathologic correspondence was performed in patients with early-stage liver cancer who had undergone [18F]fluorocholine PET/CT before tumor resection. PROCEDURES: Tumor and adjacent liver were profiled by liquid chromatography mass spectrometry, quantifying phosphatidylcholine species by mass-to-charge ratio. For clinical-radiopathologic correlation, HCC profiles were reduced to two orthogonal principal component factors (PCF1 and PCF2) accounting for 80 % of total profile variation.
RESULTS: Tissues from 31 HCC patients and 4 intrahepatic cholangiocarcinoma (ICC) patients were analyzed, revealing significantly higher levels of phosphocholine, CDP-choline, and highly saturated phosphatidylcholine species in HCC tumors relative to adjacent liver and ICC tumors. Significant loading values for PCF1 corresponded to phosphatidylcholines containing poly-unsaturated fatty acids while PCF2 corresponded only to highly saturated phosphatidylcholines. Only PCF2 correlated significantly with HCC tumor-to-liver [18F]fluorocholine uptake ratio (ρ = 0.59, p < 0.0005). Sensitivity for all tumors based on an abnormal [18F]fluorocholine uptake ratio was 93 % while sensitivity for HCC based on increased tumor [18F]fluorocholine uptake was 84 %, with lower levels of highly saturated phosphatidylcholines in tumors showing low [18F]fluorocholine uptake.
CONCLUSION: Most HCC tumors contain high levels of saturated phosphatidylcholines, supporting their dependence on de novo fatty acid metabolism for phospholipid membrane synthesis. While [18F]fluorocholine PET/CT can serve to identify these lipogenic tumors, its imperfect diagnostic sensitivity implies metabolic heterogeneity across HCC and a weaker lipogenic phenotype in some tumors.

Entities:  

Keywords:  Fatty acids; Fluorocholine; Hepatocellular carcinoma; Phosphatidylcholine; Positron emission tomography

Mesh:

Substances:

Year:  2017        PMID: 27787742      PMCID: PMC5407951          DOI: 10.1007/s11307-016-1020-3

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  36 in total

Review 1.  Choline transport for phospholipid synthesis.

Authors:  Vera Michel; Zongfei Yuan; Shobha Ramsubir; Marica Bakovic
Journal:  Exp Biol Med (Maywood)       Date:  2006-05

2.  PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT.

Authors:  Jean-Noël Talbot; Fabrice Gutman; Laetitia Fartoux; Jean-Didier Grange; Nathalie Ganne; Khaldoun Kerrou; Dany Grahek; Françoise Montravers; Raoul Poupon; Olivier Rosmorduc
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06-27       Impact factor: 9.236

3.  Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression.

Authors:  Mika Hilvo; Carsten Denkert; Laura Lehtinen; Berit Müller; Scarlet Brockmöller; Tuulikki Seppänen-Laakso; Jan Budczies; Elmar Bucher; Laxman Yetukuri; Sandra Castillo; Emilia Berg; Heli Nygren; Marko Sysi-Aho; Julian L Griffin; Oliver Fiehn; Sibylle Loibl; Christiane Richter-Ehrenstein; Cornelia Radke; Tuulia Hyötyläinen; Olli Kallioniemi; Kristiina Iljin; Matej Oresic
Journal:  Cancer Res       Date:  2011-03-17       Impact factor: 12.701

Review 4.  Choline metabolism in malignant transformation.

Authors:  Kristine Glunde; Zaver M Bhujwalla; Sabrina M Ronen
Journal:  Nat Rev Cancer       Date:  2011-11-17       Impact factor: 60.716

Review 5.  Positron emission tomography in hepatobiliary and pancreatic malignancies: a review.

Authors:  Billy Y Lan; Sandi A Kwee; Linda L Wong
Journal:  Am J Surg       Date:  2012-03-30       Impact factor: 2.565

6.  Hepatobiliary cancers, version 2.2014.

Authors:  Al B Benson; Michael I D'Angelica; Thomas A Abrams; Chandrakanth Are; P Mark Bloomston; Daniel T Chang; Bryan M Clary; Anne M Covey; William D Ensminger; Renuka Iyer; R Kate Kelley; David Linehan; Mokenge P Malafa; Steven G Meranze; James O Park; Timothy Pawlik; James A Posey; Courtney Scaife; Tracey Schefter; Elin R Sigurdson; G Gary Tian; Jean-Nicolas Vauthey; Alan P Venook; Yun Yen; Andrew X Zhu; Karin G Hoffmann; Nicole R McMillian; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2014-08       Impact factor: 11.908

Review 7.  The metabolomic window into hepatobiliary disease.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  J Hepatol       Date:  2013-05-25       Impact factor: 25.083

Review 8.  How cancer metabolism is tuned for proliferation and vulnerable to disruption.

Authors:  Almut Schulze; Adrian L Harris
Journal:  Nature       Date:  2012-11-15       Impact factor: 49.962

Review 9.  The potential of ¹¹C-acetate PET for monitoring the Fatty acid synthesis pathway in Tumors.

Authors:  Laura M Deford-Watts; Akiva Mintz; Steven J Kridel
Journal:  Curr Pharm Biotechnol       Date:  2013       Impact factor: 2.837

10.  Kinetic Modeling Application to (18)F-fluoroethylcholine Positron Emission Tomography in Patients with Primary and Recurrent Prostate Cancer Using Two-tissue Compartmental Model.

Authors:  Mustafa Takesh
Journal:  World J Nucl Med       Date:  2013-09
View more
  8 in total

1.  PET/CT with 18F Fluorocholine as an Imaging Biomarker for Chronic Liver Disease: A Preliminary Radiopathologic Correspondence Study in Patients with Liver Cancer.

Authors:  Sandi A Kwee; Linda Wong; Owen T M Chan; Sumodh Kalathil; Naoky Tsai
Journal:  Radiology       Date:  2018-01-09       Impact factor: 11.105

2.  Transcriptomics Associates Molecular Features with 18F-Fluorocholine PET/CT Imaging Phenotype and Its Potential Relationship to Survival in Hepatocellular Carcinoma.

Authors:  Sandi A Kwee; Maarit Tiirikainen; Miles M Sato; Jared D Acoba; Runmin Wei; Wei Jia; Loic Le Marchand; Linda L Wong
Journal:  Cancer Res       Date:  2019-02-13       Impact factor: 12.701

3.  Validation of R-2-[18F]Fluoropropionic Acid as a Potential Tracer for PET Imaging of Liver Cancer.

Authors:  Zhanwen Zhang; Shaoyu Liu; Hui Ma; Dahong Nie; Fuhua Wen; Jing Zhao; Aixia Sun; Gongjun Yuan; Shu Su; Xianhong Xiang; Ping Hu; Ganghua Tang
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

4.  Evaluation of computed tomography arterial portography scan timing using different bolus tracking methods.

Authors:  Ayaka Chiba; Kohei Harada; Yoshiya Ohashi; Kanako Numasawa; Tatsuya Imai; Shun Hayasaka
Journal:  Radiol Phys Technol       Date:  2020-02-13

Review 5.  Emerging Role for 7T MRI and Metabolic Imaging for Pancreatic and Liver Cancer.

Authors:  Debra Rivera
Journal:  Metabolites       Date:  2022-04-30

6.  Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study.

Authors:  Ximin Shi; Haiqun Xing; Xiaobo Yang; Fang Li; Shaobo Yao; Jia Congwei; Haitao Zhao; Marcus Hacker; Li Huo; Xiang Li
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-10-24       Impact factor: 9.236

7.  [18F]-choline PET/CT as an imaging biomarker for primary liver cancers.

Authors:  Zhenghong Lee
Journal:  Transl Cancer Res       Date:  2016-12       Impact factor: 1.241

8.  Beta-catenin activation and immunotherapy resistance in hepatocellular carcinoma: mechanisms and biomarkers.

Authors:  Sandi A Kwee; Maarit Tiirikainen
Journal:  Hepatoma Res       Date:  2021-01-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.